New innovations in immunotherapy are transforming the treatment paradigm in early-stage non-small cell lung cancer (NSCLC) and significantly improving patient survival. Tune in to this recording from a live satellite symposium offered in conjunction with the Society for Immunotherapy of Cancer (SITC) 2024 meeting. Hear leading experts as they dive in to explore clinical implications of emerging evidence on novel immunotherapeutic regimens, including patient selection, treatment response and monitoring, toxicity management, and quality of life considerations. This session also features clinical case discussions with the experts.
- Provider:PRIME Education, Inc. (PRIME®)
- Activity Link: https://primeinc.org/online/delivering-latest-evidence-treatment-early-stage-nsclc-academic-community
- Start Date: 2024-12-06 06:00:00
- End Date: 2024-12-06 06:00:00
- Credit Details: IPCE Credits: 1.0 hours
AAPA Category 1 Credit™️: 1.0 hours
AMA PRA Category 1 Credit™️: 1.0 hours
Nursing: 1.0 hours
Pharmacy: 1.0 hours - MOC Credit Details: ABIM - 1.0 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Merck (Any division) - Amount: 92500.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence, Learner/Team Performance
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Medical Oncology
Subscribe
Login
0 Comments
Oldest